Dr. Yunfei Yuan received his medical degree from Zhongshan (Sun Yat-sen) Medical College, Guangzhou, CHINA in 1983. From 1983 to 1986, He got his resident and research training in Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China. Dr Yuan entered the same university for his postgraduate study under the supervision of Professor Ji-Fu Wang in 1986 and got his Master of Medicine in 1989.

He has been a surgeon in the department of abdominal oncology in this cancer center from 1989 to 1997 and the department of hepatobiliary oncology in this cancer center since 1997. Dr. Yuan was promoted to associate professor in 1997 and full professor in 2004.

Dr. Yuan’s clinical practice and research focuses on hepatic and biliary malignancies. He is skillful at orthotopic liver transplantation and hepatectomy, including left (right) hemi-hepatectomy or trisegmentectomy and two-step hepatectomy, and pancreatoduodenectomy. He also performs trans catheter hepatic artery chemoembolization for liver cancer. He is the key member of Multi-Disciplinary Team (MDT) for the treantment of colorectal cancer liver metastases (CRLM) and finish the resection of CRLM of most cases in this cancer center. He is the pioneer in China to evaluate the hepatic functional reserve for patients with hepatocellular carcinoma with one parameter, retention rate of Indocyanine Green at 15 minutes (ICGR15), which help to decrease the morbidity of hepatic failure after hepatectomy or chemoembolization.

Recommended by Ministry of Health of CHINA, Dr Yuan got World Health Organization Fellowship in 1998. He worked in Baylor College of Medicine (BCM) from August 1998 to July 2000 and M.D. Anderson Cancer Center (MDA) from August 2000 to August 2001 as visiting scholar, both in Houston, Texas, USA. He got training in tumor molecular biology, as well as in clinics of hepatic and biliary carcinoma. He found that hyper methylation of CpG islands is the mechanism by which SYK is silenced in breast cancer and re-expression of SYK by inhibition of DNA methylation suppresses breast cancer cell invasiveness in MDA.

Currently, Dr. Yuan’s research interest include biomarkers of recurrence and prognosis for HCC, carcinogenesis of HCC, the optimal treatment of hepatocellular carcinoma with portal hypertension. There are 2 associate professors, 5 postgraduate students, 1 technician and 1 research nurse in his group.
 
Last updated: 8 April 2016

1978 - 1983  MB, Zhongshan Medical College
1986 - 1989  MM, Sun Yat-Sen University of Medical Science
1998 - 2000 Fellowship, Baylor College of Medicine, the United States
2000 - 2001 Fellowship, M.D. Anderson Cancer Center, the United States

2014

(1) Jian Hong, Yunfei Yuan*, Jianping Wang, Yadi Liao, Ruhai Zou, Chuanlong Zhu, Binkui Li, Yi Liang, Pinzhu Huang, Zongwei Wang, Wenyu Lin, Yixin Zeng, Jia Le Dai, and Raymond T. Chung*. Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma. Cancer Research 2014, 74(6):1845-56 (2014 IF=9.329)

(2) Binkui Li, Pinzhu Huang, Jiliang Qiu, Yadi Liao, Jian Hong, Yunfei Yuan*. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Medical Oncology, 2014, 31(10): 230. (2014 IF=2.634)

(3) Jun Huang, Qijiong Li, Yun Zheng, Jingxian Shen, Jiliang Qiu, Binkui Li, Ruhai Zou, Jianping Wang and Yunfei Yuan*. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer 2014, 14:818. (2014 IF=3.362)

(4) Bin-Kui Li, Pin-Zhu Huang, Ji-Liang Qiu, Ya-Di Liao, Jian Hong and Yun-Fei Yuan*. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagnostic Pathology 2014, 9:226.(2014 IF=2.597)

(5) Cong Li, Yangkui Gu, Ming Zhao, Yunfei Yuan, Fenghua Wang, Zhiqiang Wang, Wang Li, Huiyan Luo, Cui Chen, Gong Chen, Peirong Ding, Xiaojun Wu, Zhenhai Lu, Zhizhong Pan, Ruihua Xu, Youjian He, Desen Wan, Yuhong Li. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer chemotherapy and pharmacology. 2014, 4(5):1079-87.

(6) Stella Chai, Man Tong, Kai Yu Ng, Pak Shing Kwan, Yuen Piu Chan, Tsun Ming Fung, Terence K Lee, Nathalie Wong, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan, Stephanie Ma. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget. 2014, 5(14):5725-35.

(7) Longhui Cao, Yi Chang, Wenqian Lin, Jianhua Zhou, Hongying Tan, Yunfei Yuan, Weian Zeng. Long-term survival after resection of hepatocelluar carcinoma: a potential risk associated with the choice of postoperative analgesia. Anesthesia & Analgesia. 2014, 118(6):1309-16.

(8) Yin Xie, Rong-Rong Wei, Guo-Liang Huang, Mei-Yin Zhang, Yun-Fei Yuan, Hui-Yun Wang. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Medical Oncology. 2014, 31(3):844.

(9) Ming Liu, Yan Li, Leilei Chen, Tim Hon Man Chan, Yangyang Song, Li Fu, Ting-Ting Zeng, Yong-Dong Dai, Ying-Hui Zhu, Juan Chen, Yun-Fei Yuan, Xin-Yuan Guan. Allele-specific imbalance of oxidative stress-induced growth inhibitor 1 associates with progression of hepatocellular carcinoma. Gastroenterology. 2014, 146(4):1084-96.

(10) Lulu Liu, Yongdong Dai, Jinna Chen, Tingting Zeng, Yan Li, Leilei Chen, Ying-Hui Zhu, Jiangchao Li, Stephanie Ma, Dan Xie, Yun-Fei Yuan, Xin-Yuan Guan. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 2014, 59(2):531-43.

(11) Tim Hon Man Chan, Chi Ho Lin, Lihua Qi, Jing Fei, Yan Li, Kol Jia Yong, Ming Liu, Yangyang Song, Raymond Kwok Kei Chow, Vanessa Hui En Ng, Yun-Fei Yuan, Daniel G Tenen, Xin-Yuan Guan, Leilei Chen. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2014, 63(5):832-43.

2015

(12) Wei He, Qingli Zeng, Yun Zheng, Meixian Chen, Jingxian Shen, Jiliang Qiu, Miao Chen,  Ruhai Zou, Yadi Liao, Qijiong Li, Xianqiu Wu, Binkui Li* and Yun-Fei Yuan*. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer 2015, 15:263. (2014 IF=3.362)

(13) Xianqiu Wu, Binkui Li, Jiliang Qiu, Jingxian Shen, Yun Zheng, Qijong Li, Yadi Liao, Wei He, Ruhai Zou and Yunfei Yuan*. Hepatectomy versus hepatectomy with lymphadenectomy in hepatocellular carcinoma – A prospective, randomized controlled clinical trial. Journal of Clinical Gastroenterology 2015;49:520-528（2014 IF=3.498）

(14) Jiliang Qiu, Yun Zheng, Jingxian Shen, Zeng QingAn, Ruhai Zou, Yadi Liao, Wei He, Qijiong Li, Guihua Chen, Binkui Li, Yunfei Yuan*. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 2015, 158(5):1235-1243.（2014 IF=3.38）

(15) Lingxi Jiang, Dora Lai-Wan Kwong, Yan Li, Ming Liu, Yun-Fei Yuan, Li Fu, Xin-Yuan Guan*. HBP21, a chaperone of heat shock protein 70, functions as a tumor suppressor in hepatocellular carcinoma. Carcinogenesis. 2015, 36(10):1111-20.

(16) Yangyang Song, Guangjin Pan, Leilei Chen, Stephanie Ma, Tingting Zeng, Tim Hon Man Chan, Lei Li, Qizhou Lian, Raymond Chow, Xiujuan Cai, Yan Li, Ming Liu, Yun Li, Yinghui Zhu, Nathalie Wong, Yun-Fei Yuan, Duanqing Pei, Xin-Yuan Guan*. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells. Gastroenterology. 2015, 149(4):1068-81.

(17) Man Tong, Tsun-Ming Fung, Steve T Luk, Kai-Yu Ng, Terence K Lee, Chi-Ho Lin, Judy W Yam, Kwok Wah Chan, Fai Ng, Bo-Jian Zheng, Yun-Fei Yuan, Dan Xie, Chung-Mau Lo, Kwan Man, Xin-Yuan Guan, Stephanie Ma. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma. Stem Cell Reports. 2015, 5(1):45-59.

(18) Xue-Jia Lin, Yutian Chong, Zhi-Wei Guo, Chen Xie, Xiao-Jing Yang, Qi Zhang, Sheng-Ping Li, Yujuan Xiong, Yunfei Yuan, Jun Min, Wei-Hua Jia, Yusheng Jie, Min-Shan Chen, Mei-Xian Chen, Jian-Hong Fang, Chunxian Zeng, Yaojun Zhang, Rong-Ping Guo, Yuankai Wu, Guoli Lin, Limin Zheng, Shi-Mei Zhuang. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. The Lancet Oncology. 2015, 16(7):804-15.

(19) Zhong-Guo Zhou, Xing-Rong Zheng, Qian Zhou, Ming Shi, Yao-Jun Zhang, Rong-Ping Guo, Yun-Fei Yuan, Min-Shan Chen, Xiao-Jun Lin, Xiang-Ming Lao, Sheng-Ping Li. Impact of oral anti-hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese Journal of Cancer. 2015, 34(5):205-16.

(20) Jian-Hong Fang, Hui-Chao Zhou, Chong Zhang, Li-Ru Shang, Lei Zhang, Jing Xu, Limin Zheng, Yunfei Yuan, Rong-Ping Guo, Wei-Hua Jia, Jing-Ping Yun, Min-Shan Chen, Yaojun Zhang, Shi-Mei Zhuang. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology. 2015, 62(2):452-65.

(21) Fang Zheng, Yi-Ji Liao, Mu-Yan Cai, Tian-Hao Liu, Shu-Peng Chen, Pei-Hong Wu, Long Wu, Xiu-Wu Bian, Xin-Yuan Guan, Yi-Xin Zeng, Yun-Fei Yuan, Hsiang-Fu Kung, Dan Xie. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. PLoS Genetics. 2015, 11(2):e1004873.

(22) Jian Wang, Ming Liu, Leilei Chen, Tim Hon Man Chan, Lingxi Jiang, Yun-Fei Yuan, Xin-Yuan Guan. Overexpression of N-terminal kinase like gene promotes tumorigenicity of hepatocellular carcinoma by regulating cell cycle progression and cell motility. Oncotarget. 2015, 6(3):1618-30.

(23) Sheng-Long Ye*, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Christina SM YIP, Zhengguang Lu. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget. 2015, 7(6):6639

2016

(24) Pinghua Yang, Jiliang Qiu, Jun Li, Dong Wu, Xuying Wan, Wan Yee Lau, Yunfei Yuan*, and Feng Shen*. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Annals of Surgery 2016, 263(4):778–786 (2014 IF=8.327)

 

Last updated: April 2016 by International Office, Sun Yat-sen University Cancer Center